HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of IV Insulin Dosing Strategies for Hyperkalemia in the Emergency Department.

Abstract
The objectives of this study were to evaluate the safety and efficacy of insulin dosing of less than 10 units versus 10 units in patients receiving hyperkalemia treatment.
DESIGN:
Retrospective single-center study.
SETTING:
Emergency department at a large academic medical center in the United States.
PATIENTS:
Seven hundred adults treated for hyperkalemia with IV regular insulin between April 1, 2013, and September 27, 2018.
INTERVENTIONS:
Patients that received less than 10 units of insulin were compared to those that received 10 units of insulin.
MEASUREMENTS AND MAIN RESULTS:
Patients treated with less than 10 units had significantly lower frequency of hypoglycemia (11.2% vs 17.6%; p = 0.008). Reduction in serum potassium was significantly more modest in size in patients treated with less than 10 units (mean reduction 0.94 ± 0.71 mMol/L) compared with patients treated with 10 units (mean reduction 1.11 ± 0.8 mMol/L; p = 0.008). There were no statistically significant differences between groups in time to hypoglycemia, nadir serum glucose, severe hypoglycemia (<40 mg/dL), dextrose requirements, use of concurrent agents for hyperkalemia, need for repeat insulin dosing, length of stay, or mortality.
CONCLUSIONS:
Patients treated for hyperkalemia with insulin doses less than 10 units had reduced frequency of hypoglycemia; however, potassium reduction post treatment was more modest in these patients. These findings suggest providers choosing to administer 10 units IV insulin should ensure patients have adequate monitoring for hypoglycemia.
AuthorsKayvan Moussavi, Lani T Nguyen, Henry Hua, Scott Fitter
JournalCritical care explorations (Crit Care Explor) Vol. 2 Issue 4 Pg. e0092 (Apr 2020) ISSN: 2639-8028 [Electronic] United States
PMID32426734 (Publication Type: Journal Article)
CopyrightCopyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: